Detection of primary sites in unknown primary tumors using FDG-PET or FDG-PET/CT

BMC Research Notes

Volumn 4, Issue , 2011, Pages

  Park, Jong Sun ^a   Yim, Jae Joon ^b   Kang, Won Jun ^b   Chung, June Key ^b   Yoo, Chul Gyu ^b   Kim, Young Whan ^b   Han, Sung Koo ^b   Shim, Young Soo ^b   Lee, Sang Min ^b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952347955     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-4-56     Document Type: Article

References (20)

1. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. JL Abbruzzese MC Abbruzzese R Lenzi KR Hess MN Raber, J Clin Oncol 1995 13 2094 2103 7636553
2. Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. T Le Chevalier E Cvitkovic P Caille J Harvey G Contesso M Spielmann J Rouesse, Arch Intern Med 1988 148 2035 2039 10.1001/archinte.148.9.2035 3046543
3. Continuous infusion 5-fluorouracil, etoposide and cis- diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin. MN Raber J Faintuch JL Abbruzzese C Sumrall P Frost, Ann Oncol 1991 2 519 520 1911461
4. Diagnostic strategies in cervical carcinoma of an unknown primary (CUP). I Haas TK Hoffmann R Engers U Ganzer, Eur Arch Otorhinolaryngol 2002 259 325 333 10.1007/s004050100408 12115082 (Pubitemid 34762310)
5. FDG PET/CT in carcinoma of unknown primary. TC Kwee S Basu G Cheng A Alavi, Eur J Nucl Med Mol Imaging 2010 37 635 644 10.1007/s00259-009-1295-6 19882152
6. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. KE Rusthoven M Koshy AC Paulino, Cancer 2004 101 2641 2649 10.1002/cncr.20687 15517576 (Pubitemid 39532297)
7. The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. P Seve C Billotey C Broussolle C Dumontet JR Mackey, Cancer 2007 109 292 299 10.1002/cncr.22410 17167760 (Pubitemid 46116455)
8. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. TC Kwee RM Kwee, Eur Radiol 2009 19 731 744 10.1007/s00330-008-1194-4 18925401
9. False positive and false negative FDG-PET scans in various thoracic diseases. JM Chang HJ Lee JM Goo HY Lee JJ Lee JK Chung JG Im, Korean J Radiol 2006 7 57 69 10.3348/kjr.2006.7.1.57 16549957
10. The detection of unknown primary tumors in patients with cervical metastases by dual-head positron emission tomography. MP Stokkel CH Terhaard GJ Hordijk PP van Rijk, Oral Oncol 1999 35 390 394 10.1016/S1368-8375(98)00129-8 10645404 (Pubitemid 29276974)
11. Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors. AA OS NJ Fischbein GR Caputo MJ Kaplan DC Price MI Singer WP Dillon RA Hawkins, Radiology 1999 210 177 181 9885604 (Pubitemid 29004300)
12. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities. G Regelink J Brouwer R de Bree J Pruim BF van der Laan W Vaalburg OS Hoekstra EF Comans A Vissink CR Leemans JL Roodenburg, Eur J Nucl Med Mol Imaging 2002 29 1024 1030 10.1007/s00259-002-0819-0 12173016
13. Role of 18F-FDG PET-CT imaging for the detection of an unknown primary tumour: preliminary results in 21 patients. C Nanni D Rubello P Castellucci M Farsad R Franchi S Toso C Barile L Rampin O Nibale S Fanti, Eur J Nucl Med Mol Imaging 2005 32 589 592 10.1007/s00259-004-1734-3 15726356 (Pubitemid 41214202)
14. Unknown primary tumors: detection with dual-modality PET/CT - initial experience. A Gutzeit G Antoch H Kuhl T Egelhof M Fischer E Hauth S Goehde A Bockisch J Debatin L Freudenberg, Radiology 2005 234 227 234 10.1148/radiol.2341031554 15564390 (Pubitemid 39662772)
15. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. E Pelosi M Pennone D Deandreis A Douroukas M Mancini G Bisi, Q J Nucl Med Mol Imaging 2006 50 15 22 16557200
16. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). U Lassen G Daugaard A Eigtved K Damgaard L Friberg, Eur J Cancer 1999 35 1076 1082 10.1016/S0959-8049(99)00077-5 10533451 (Pubitemid 29339190)
17. FDG PET detection of unknown primary tumors. KH Bohuslavizki S Klutmann S Kroger U Sonnemann R Buchert JA Werner J Mester M Clausen, J Nucl Med 2000 41 816 822 10809197 (Pubitemid 30266025)
18. Whole-body positron emission tomography using fluorodeoxyglucose in patients with metastases of unknown primary tumours (CUP syndrome). JL Alberini T Belhocine R Hustinx F Daenen P Rigo, Nucl Med Commun 2003 24 1081 1086 10.1097/00006231-200310000-00008 14508164
19. Positron-emission tomography and assessment of cancer therapy. ME Juweid BD Cheson, N Engl J Med 2006 354 496 507 10.1056/NEJMra050276 16452561 (Pubitemid 43200300)
20. Do metastatic tumours from an unknown primary reflect angiogenic incompetence of the tumour at the primary site? - a hypothesis. KN Naresh, Med Hypotheses 2002 59 357 360 10.1016/S0306-9877(02)00221-9 12208170